mental health conditions
Gate Neurosciences plans Phase II MDD trial with next-gen antidepressant
The company aims to start the Phase II study of its lead compound zelquistinel in Q4 2023 at sites in the US.
The company aims to start the Phase II study of its lead compound zelquistinel in Q4 2023 at sites in the US.